Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Gastro-enteropancreatic neuroendocrine tumor × Ipilimumab × 90 days × Clear all

Sponsor

Conditions

Melanoma 27 Carcinoma, Renal Cell 16 Carcinoma, Non-Small-Cell Lung 15 Neoplasm Metastasis 9 Skin Neoplasms 7 Squamous Cell Carcinoma of Head and Neck 5 Lung Neoplasms 5 Kidney Neoplasms 5 Carcinoma, Hepatocellular 5 Brain Neoplasms 5 Urinary Bladder Neoplasms 4 Neoplasms 4 Colorectal Neoplasms 4 Carcinoma, Transitional Cell 4 Carcinoma, Merkel Cell 4 Urogenital Neoplasms 3 Urethral Neoplasms 3 Small Cell Lung Carcinoma 3 Prostatic Neoplasms 3 Penile Neoplasms 3 Pancreatic Neoplasms 3 Mesothelioma, Malignant 3 Glioblastoma 3 Uveal Melanoma 2 Ureteral Neoplasms 2 Sarcoma 2 Recurrence 2 Rectal Neoplasms 2 Neuroendocrine Tumors 2 Myelodysplastic Syndromes 2

Interventions

lutetium Lu 177 dotatate 3 pasireotide 2 Octreotide 2 lanreotide 1 copper dotatate CU-64 1 abemaciclib 1 Sunitinib 1 Receptor-Like Protein Tyrosine Phosphatases, Class 2 1 Lutetium-177 1 Lutetium 1 Everolimus 1 E-7386 1 Cryotherapy 1 Acupuncture Therapy 1 Acupressure 1 11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡